1. Dahej greenfield manufacturing hub - Board approved the first \~₹150 cr plant at Dahej for a herbicide intermediate supplied to parent SCC, with environmental clearance secured for 10 years and commercialization targeted for Q2 FY2028-29. This opens a multi-decade capex cycle where management expects a sustained pipeline of similar-sized projects, each serving SCC’s global patented-molecule requirements from a site with potential to absorb growth for 10-12 years.
2. Bhavnagar second plant for SCC global molecule - A \~₹55 cr brownfield expansion to double capacity of an SCC-innovated product at Bhavnagar is approved, targeting Q4 FY27 commercialization, which would let SCIL meet 40-50% of the parent’s global requirement for this molecule. The first plant on the same site is already fully commercialized, so this second line adds revenue from a proven product with an established offtake channel.
3. Excalia Max local technical manufacturing - A \~₹10 cr brownfield project at Tarapur will manufacture the active ingredient for Excalia Max (INDIFLIN) in India, with completion and commercialization targeted by Q4 FY27. Backward integration into the technical removes import dependence for a product management calls the next blockbuster and that already exceeded internal targets in its launch year.
4. India elevated to Tier-1 for SCC’s early-stage molecule pipeline - Parent SCC has designated India as a Tier-1 country for early-stage testing of new molecules from its global discovery pipeline, on par with Japan, Brazil, and North America, and two molecules are already under trial. This structural elevation means SCIL gets access to SCC’s newest proprietary chemistries years earlier, pulling forward the domestic launch pipeline and reinforcing India’s role as a manufacturing hub for the group.
5. New royalty arrangement lifts margins on select products - SCC has waived the obligation to buy technical goods from the parent for 2-3 selected products, replacing it with a small royalty capped at ₹2 cr, allowing SCIL to source from outside. The arrangement directly improves the margin profile of these products and gives SCIL pricing flexibility to expand them in the domestic market.
6. Tarapur two-molecule addition for parent supply - Board approved \~₹10 cr in January 2026 for fitment to manufacture one fungicide and one herbicide at Tarapur for SCC, with commercialization targeted for Q4 FY2027-28. This adds two more CRAMS revenue streams at an existing site where the multipurpose plant infrastructure is already in place.
7. Biologicals portfolio scaling from FY27 - Biologicals already contribute 8-10% of revenue, well above the industry average, and management expects both the share and absolute revenue to grow meaningfully from FY27 onward after biostimulant regulatory clearances came through in late 2025. With Barrix’s regulatory approvals now largely restored and new products under evaluation from group company Valent BioSciences, the biologicals segment is positioned to accelerate from a cleared regulatory base.
8. Specialty mix shift to 30% of domestic revenue - The specialty portfolio has structurally moved from 22-24% to 30% of domestic revenues over five years, and branded formulations reached 81% of domestic sales in FY26. A richer mix of patented and branded products lifts margin quality and reduces exposure to commoditized generic price cycles.
9. Herbicides volume-led growth with Lentigo ramp - Herbicides grew 87% YoY in Q4 FY26 and 19% for the full year, driven by flumioxazin, newly launched patented rice herbicide Lentigo, and the flagship glyphosate brand Mera 71, with the company taking back zero litres from the channel in a year of industry-wide returns. Lentigo exceeded internal targets in its launch year, and the portfolio’s volume-led growth suggests sustainable demand rather than one-off price spikes.
10. CRAMS revenue step-up as projects complete - Sales to parent SCC currently run at ₹100-150 cr annually, and management expects growth from FY27 as projects under implementation get completed. With the Bhavnagar second plant and Tarapur additions targeting FY27-FY28 commercialization, the CRAMS base is set to expand from a level that is already material to exports.